Literature DB >> 8216246

Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages.

H Haddada1, M Lopez, C Martinache, T Ragot, M A Abina, M Perricaudet.   

Abstract

The efficiency of gene transfer into human blood monocyte-derived macrophages has been evaluated using a replication-defective adenovirus vector harboring a lac Z gene of E. coli as a reporter gene. Whereas, no beta-galactosidase activity was found in freshly infected purified monocytes, 40% to 80% of infected macrophages which derived from these monocytes showed a beta-galactosidase activity, 2 to 4 days after infection and lasted for at least 3 weeks. Moreover, beta-galactosidase activity was found in infected monocyte/macrophages 7 days after their injection into a human tumor preestablished in nude mice. These data indicate that it is possible to transfer and stably express a gene of potential therapeutical function into human monocyte-derived macrophages using an adenovirus vector.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216246     DOI: 10.1006/bbrc.1993.2168

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Cell engineering for muscle gene therapy: Extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes.

Authors:  E Parrish; E Peltékian; G Dickson; A L Epstein; L Garcia
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

3.  Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery.

Authors:  S Huang; R I Endo; G R Nemerow
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 4.  Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.

Authors:  B M Foxwell; J Bondeson; F Brennan; M Feldmann
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Strategies for cancer gene therapy using adenoviral vectors.

Authors:  V Descamps; M T Duffour; M C Mathieu; N Fernandez; L Cordier; M A Abina; E Kremer; M Perricaudet; H Haddada
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

6.  Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes.

Authors:  Z Toossi; L Xia; M Wu; A Salvekar
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

7.  High-resolution genetic and physical map of the Lgn1 interval in C57BL/6J implicates Naip2 or Naip5 in Legionella pneumophila pathogenesis.

Authors:  J D Growney; W F Dietrich
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

8.  A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors:  S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent.

Authors:  B Foxwell; K Browne; J Bondeson; C Clarke; R de Martin; F Brennan; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton rat.

Authors:  W Oualikene; P Gonin; M Eloit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.